Trexquant Investment LP Increases Position in Cellebrite DI Ltd. $CLBT

Key Points

• Trexquant Investment LP has increased its stake in Cellebrite DI Ltd. by 30.4% in the first quarter, owning approximately $5.77 million worth of shares after purchasing an additional 69,273 shares.
• Several analysts have revised their price targets for Cellebrite DI, with the consensus target price now at $22.40 following upgrades and downgrades from firms such as Lake Street Capital and JPMorgan Chase & Co.
• Cellebrite DI reported $113.28 million in revenue for the last quarter, exceeding analyst expectations and indicating an 18.4% increase compared to the same quarter last year.

Trexquant Investment LP raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 30.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 296,871 shares of the company's stock after purchasing an additional 69,273 shares during the quarter. Trexquant Investment LP owned 0.12% of Cellebrite DI worth $5,768,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of CLBT. Assetmark Inc. bought a new stake in shares of Cellebrite DI during the first quarter worth $33,000. Catalyst Capital Advisors LLC bought a new position in Cellebrite DI during the 1st quarter worth approximately $51,000. Virtus Advisers LLC bought a new position in Cellebrite DI during the 1st quarter worth approximately $63,000. Gen Wealth Partners Inc acquired a new position in Cellebrite DI in the fourth quarter valued at approximately $85,000. Finally, NewEdge Advisors LLC increased its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after purchasing an additional 3,352 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CLBT. Lake Street Capital cut their price target on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. JPMorgan Chase & Co. decreased their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Finally, Needham & Company LLC dropped their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $22.40.

Cellebrite DI Trading Up 1.5%

Shares of NASDAQ:CLBT traded up $0.24 during trading on Friday, reaching $16.61. The company had a trading volume of 1,482,676 shares, compared to its average volume of 1,693,068. The company has a fifty day moving average of $15.01 and a two-hundred day moving average of $17.06. The stock has a market capitalization of $3.98 billion, a P/E ratio of -21.86, a price-to-earnings-growth ratio of 3.00 and a beta of 1.28. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same period in the previous year, the business earned $0.10 earnings per share. The firm's quarterly revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.